-
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion Projects
•
China-based Huaren Pharmaceutical Co., Ltd is set to raise RMB 1.34 billion (USD 194.8 million) through a private placement of 355 million shares. The funds raised will be allocated towards several key projects, including the expansion of peritoneal dialysate production capacity, construction of a drug packaging material production base, development…
-
Alphax Bio Raises Millions for Spatial Proteomics and Tumor Immune Microenvironment Research
•
Beijing-based Alphax Bio, a developer of immune-testing technologies, has reportedly raised “tens of millions” of renminbi in a recent financing round, led solely by Cui Capital. The funds will be directed towards the clinical transformation of spatial proteomics tumor immune microenvironment assessment, the development of functional proteomics solutions, and the…
-
WuXi Biologics Reports 48.4% Revenue Growth in 2022 Financial Report
•
China-based WuXi Biologics (HKG: 2269) released its 2022 financial report for the period ending December 31, 2022. The Contract Development and Manufacturing Organization (CDMO) reported total income of RMB 15.27 billion (USD 2.237 billion), marking a 48.4% increase year-on-year (YOY). Net profits also rose by 47.1% YOY, reaching RMB 5.05…
-
Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology
•
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi in a Series C+ financing round. The round was led by Source Code Capital, with contributions from CCB Private Equity Investment, E-town Capital, Founder H Fund, and Lotus Lake Capital. The funds will be used…
-
L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development
•
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series B financing round, led by Hongfeng Venture. Additional investors included Oriental Wisdom Capital, Zhongchuang Yongjian (Ningbo) Venture Capital, and existing investor Qiao Jing Capital. The funds will be directed towards Phase I clinical studies for…
-
T&L Biotechnology Secures RMB 100 Million in Series A Financing
•
Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB 100 million (USD 14.53 million) in a Series A financing round. The round was led by Harvest Capital and Fortune Capital, with participation from Zhiheng (Yantai) Entrepreneurship Service Center. The funds will be used to…
-
Vas Healthcare Raises RMB 100 Million in Angel Financing for Robot Development
•
Vas Healthcare, a developer of vascular interventional surgery robots based in Beijing, has reportedly raised RMB 100 million (USD 14.5 million) in an angel financing round. The round was co-led by CAS Investment and Noah Capital. The funds will be used to support technology research and development, new product iteration,…
-
Asiflyer Bio Raises Millions in Pre-Series A Funding for Botox and ZFP Technology
•
Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by DNE Capital, with participation from Yuanbio Venture Capital, its angel financing investor. The funds will be used to advance the industrialization of the fourth-generation…
-
Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities
•
China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan Lifeline’s (TYO: 7575) China unit Synexmed (Shenzhen) Co., Ltd for an undisclosed amount. This acquisition will enhance Enlight’s capabilities in the vascular intervention market. About Synexmed and the AcquisitionFounded in 2005, Synexmed specializes in supplying…
-
Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development
•
Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel financing round led exclusively by Dalton Venture. The proceeds will be utilized for the extraction of high-purity active collagen, the in-depth development of oral bone tissue-guided membrane adhesive and artificial cornea, and the establishment of…
-
Neowise Biotechnology Secures RMB 200 Million in Series A+ Financing Round
•
Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised close to RMB 200 million (USD 29 million) in a Series A+ financing round. This investment will support the company’s ongoing research and development efforts in TCR therapies. Investor ParticipationThe financing round was led by…
-
Singde Yiyang Secures Series A Financing to Expand Wellness Services in China
•
Singde Yiyang, a leading wellness service provider based in Qingdao, reportedly raised “hundreds of millions” of renminbi in a Series A financing round led by Genertec Investment. The company plans to implement a “1+X+N” layout, covering key regions and cities in China, with a target of over 10,000 beds. Company…
-
Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies
•
China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKSE), according to the exchange. The offering will be sponsored by CICC. This move marks a significant step in Laekna’s growth strategy as it seeks to raise capital to further…
-
Immunophage Biotech Raises RMB 200 Million in Series B1 Financing for Clinical Trials
•
Nanjing-based Immunophage Biotech Co., Ltd reportedly raised close to RMB 200 million (USD 29.1 million) in the first phase of a Series B1 financing round, led by ZBJL Capital and supported by debt financing. The funds will be used to advance Phase II clinical studies for first-tier products and Phase…
-
Silicon Valley Bank Collapse Impacts Tech and Biotech Sectors Globally
•
The tech and biotech sectors are grappling with the implications of the collapse of US-based Silicon Valley Bank (SVB; Nasdaq: SIVB), which specialized in working with the tech and biopharma venture capital sectors. The bank was seized by the US government’s Federal Deposit Insurance Corporation (FDIC) on Friday, March 10,…
-
Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development
•
Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised USD 50 million in a Series B financing round. The round was led by INCE Capital and Qiming Venture Partners, with contributions from TF Capital, LongRiver Investments, 3SBio, Octagon Capital, and Lichen Private Equity Fund.…
-
Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development
•
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100 million in a Series B financing round. The round was led by Hankang Capital and included participation from Cybernaut, Yangzijiang Funds, Ennovation Ventures, and Matrix Partners China. The proceeds will be used to enhance the…
-
HuiLiao Biomedical Raises RMB 100 Million in Pre-Series A Round for mRNA Development
•
China-based nucleic acid drug specialist Suzhou HuiLiao Biomedical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 14.35 million) in a pre-Series A financing round. The round was led by MING Bioventures, with participation from Shunwei Capital, China-Singapore Suzhou Industrial Park Private Equity Management Co., Ltd, and existing…
-
Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Therapies
•
China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million) in a Series A financing round. The round was led by Bainuo Capital, with participation from existing investor Hankang Capital. The proceeds will be used to support research and development and clinical studies for multiple…
-
Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development
•
Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by HM Capital, with a contribution from Northern Lights Venture Capital. The proceeds will be used to support clinical studies, new product research…
